市場調查報告書
商品編碼
1054313

日本藥物輸送設備市場:增長、趨勢、COVID-19 的影響、預測(2022-2027 年)

Japan Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 68 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,日本藥物輸送設備市場預計將以約 4.5% 的複合年增長率增長。

市場的主要驅動力是慢性病的增加和技術進步。在日本,癌症患者、呼吸系統疾病和糖尿病患者的人數不斷增加,藥物輸送裝置的引進有望得到推動,整個市場有望擴大。

本報告對日本給藥裝置市場進行調查和分析,並提供市場促進因素、制約因素、按給藥途徑/使用/最終用戶的市場分析以及競爭情況。

目錄

第一章介紹

第二章調查方法

第 3 章執行摘要

第四章市場動態

  • 市場概況
  • 市場驅動力
    • 慢性病患病率增加
    • 技術進步
  • 市場限制
    • 針刺傷風險
  • 波特五力分析

第5章市場部

  • 按給藥途徑
    • 注入
    • 外用
    • 目鏡
    • 其他給藥途徑
  • 按應用
    • 癌症
    • 心血管
    • 糖尿病
    • 傳染病
    • 其他用途
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶

第6章競爭態勢

  • 公司簡介
    • Mylan N.V.
    • Antares Pharma, Inc.
    • Tasei Kako Co. Ltd.
    • GlaxoSmithKline Plc
    • Novartis AG
    • Bayer AG
    • Becton, Dickinson and Company
    • Johnson & Johnson
    • 3M Company

第7章 市場機會與今後動向

目錄
Product Code: 47857

The Japan Drug Delivery Devices Market is expected to register a CAGR of nearly 4.5% during the forecast period. The major factors driving the Japan Drug Delivery Devices Market are the rising prevalence of chronic diseases and technological advancements.

Drug delivery devices help in delivering the drugs which are beneficial for the targeted population to recover faster. In addition, a rising number of cancers, respiratory are diabetic patients in Japan will promote the adoption of drug delivery devices and drive the overall market. For instance, according to the estimates of the National Cancer Center - Center for Cancer Control and Information Services, the cancer incidence in 2018 was 1,013,600 in Japan, while the most common types of cancer were colorectum, stomach, lung, breast, and prostate cancer. Thus, owing to the above-mentioned factors is expected to drive market growth over the forecast period.

Key Market Trends

By Application Cancer is Estimated to Witness a Healthy Growth Over The Forecast Period

Over the years, cancer incidence and mortality have increased in Japan. For instance, according to the World Health Organization (WHO), 2018 statistics indicate that the deaths due to cancer increased to nearly 409,400, in Japan. The increasing mortality rate has been a concerning factor for the Japanese government over the years. As a result, the government and other organizations are taking initiatives to spread awareness regarding cancer and its treatments which is expected to boost the market. Thus, the rising prevalence of cancer and the presence of better R&D infrastructure in the country is expected to drive market growth in the near future.

Competitive Landscape

The Japan Drug Delivery Devices Market is fragmented competitive and consists of several major players. Some of the companies which are currently dominating the market are Mylan N.V., ANTARES PHARMA, INC., Tasei Kako Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Bayer AG, Becton, Dickinson and Company, Johnson & Johnson and 3M Company.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Chronic Diseases
    • 4.2.2 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Risk of Needlestick Injuries
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Route of Administration
    • 5.1.1 Injectable
    • 5.1.2 Topical
    • 5.1.3 Ocular
    • 5.1.4 Other Route of Administration
  • 5.2 By Application
    • 5.2.1 Cancer
    • 5.2.2 Cardiovascular
    • 5.2.3 Diabetes
    • 5.2.4 Infectious diseases
    • 5.2.5 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End Users

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Mylan N.V.
    • 6.1.2 Antares Pharma, Inc.
    • 6.1.3 Tasei Kako Co. Ltd.
    • 6.1.4 GlaxoSmithKline Plc
    • 6.1.5 Novartis AG
    • 6.1.6 Bayer AG
    • 6.1.7 Becton, Dickinson and Company
    • 6.1.8 Johnson & Johnson
    • 6.1.9 3M Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS